Eli Lilly’s Peresolimab and LOXO-783 Gain Tacit Clinical Trial Approvals in China
The Center for Drug Evaluation (CDE) in China has granted tacit clinical trial approvals to...
Auto-immune
Novartis’ Cosentyx Gains Approval for New Doses in China
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced receiving marketing approval for two new specifications...
Proheal Pharmaceuticals Initiates Clinical Study for PHP1003 in Thyroid-Associated Ophthalmopathy
Proheal Pharmaceuticals, a Suzhou-based developer of drugs for ophthalmology and autoimmune diseases, announced the first...
Luye Pharma’s Long-Acting IL-4Rα Antibody BA2101 Gains CDE Approval
China-based Luye Pharma Group (HKG: 2186) announced that its controlling subsidiary Shandong Boan Biotechnology Co.,...
Ascentage Pharma Files for Phase Ib/II Study of Bcl-2 Inhibitor in Systemic Lupus Erythematosus
Suzhou-based Ascentage Pharma (HKG: 6855) has announced the submission of a clinical filing with the...
Bio-Thera’s BAT1806 Biosimilar Accepted for Review by European Medicine Agency
China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that a Biologic License Application (BLA) for...
Zelgen’s Jacktinib Shows Strong Efficacy in Phase III Myelofibrosis Study
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has published major data from a Phase III...
RemeGen’s Telitacicept Receives FDA Orphan Drug Designation for Myasthenia Gravis
China-based pharma firm RemeGen (HKG: 9995, SHA: 688331) has announced receiving Orphan Drug Designation (ODD)...
Harbour BioMed Licenses Batoclimab to CSPC’s NBP Pharma for Greater China
Harbour BioMed (HKG: 2142), a biotech company operating out of the United States, the Netherlands,...
Connect Biopharma’s CBP-201 Shows Positive Results in Atopic Dermatitis Study
China-based Connect Biopharmaceuticals Ltd has announced the topline results of a pivotal clinical study for...
Kira Pharmaceuticals Gets FDA Green Light for Phase II Study of KP104 in SLE-TMA
Kira Pharmaceuticals, a Sino-US biotech company, has announced that it has received approval from the...
Alphamab Oncology’s KN019 Achieves Primary Endpoint in Phase II RA Study
Suzhou-based biotech Alphamab Oncology (HKG: 9966) has announced that its China-based Phase II KN019-201 study,...
WuXi Biologics Partners with neoX Biotech to Advance AI-Driven Drug Development
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has entered into...
Simcere Grants Almirall Global Rights to Autoimmune Drug SIM0278
China’s Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into a licensing agreement with...
Harbour BioMed Doses First Subject in Phase I Study for HBM9378 in China
China-based Harbour BioMed (HKG: 2142) has announced the completion of the first subject dosing in...
Hansoh Pharmaceutical Licenses KiOmedine One for Osteoarthritis Treatment
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a licensing agreement with Belgium’s...
Everest Medicines Gains CDE Approval for EVER001 Phase Ib Study
China-based biotech Everest Medicines (HKG: 1952) has announced that it has received approval from the...
Zelgen Biopharmaceuticals Gains NMPA Approval for Jacktinib Clinical Trial in SLE
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...
RemeGen Announces Positive Phase III Results for Telitacicept in SLE
China-based pharma firm RemeGen (HKG: 9995) has announced the conclusion of a Phase III confirmatory...
Worg Pharmaceuticals Raises RMB 400 Million in Series B Funding
Worg Pharmaceuticals, a Hangzhou-based developer of novel allergic drugs, reportedly raised RMB 400 million (USD...